Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan:8:e2100163.
doi: 10.1200/GO.21.00163.

HIV and Hodgkin Lymphoma Survival: A Prospective Study in Botswana

Affiliations

HIV and Hodgkin Lymphoma Survival: A Prospective Study in Botswana

Kaelo Moahi et al. JCO Glob Oncol. 2022 Jan.

Abstract

Purpose: People living with HIV (PLWH) experience increased risk of Hodgkin lymphoma (HL) despite effective initiation of antiretroviral therapy (ART). In high-income countries, outcomes following HIV HL have been reported to be non-differential, or inferior for PLWH. We sought to assess the effect of HIV on HL survival in Botswana, an African country with a generalized HIV epidemic and high ART coverage, to describe a context more reflective of global HIV populations.

Patients and methods: In the Thabatse Cancer Cohort, consenting participants initiating treatment for HL at one of four cancer centers in Botswana were enrolled from 2010 to 2020. Patients were followed quarterly for up to 5 years. The impact of HIV on survival following treatment initiation was assessed using an inverse probability-weighted Cox marginal structural model adjusted for age, performance status, and disease stage.

Results: Seventy-eight new HL cases were enrolled, 47 (60%) were PLWH and 31 (40%) were HIV-uninfected. Baseline characteristics were similar between groups. The majority (61%) of patients presented with regional disease (stage I or II) with no statistically significant difference by HIV status (P = .38). Nearly all (87%) PLWH participants were on ART before their HL diagnosis (median ART duration 42 months), and median CD4 count was 413 cells/μL (interquartile range 253-691). Survival, in unadjusted analyses, was lower among patients without HIV compared with PLWH (log rank P = .021). In adjusted analysis, HIV infection was not significantly associated with survival in inverse probability-weighted Cox model (hazard ratio 0.43; 95% CI, 0.16 to 1.16; P = .094).

Conclusion: In this cohort of patients treated for HL in Botswana, survival in PLWH (87% on long-standing ART) was at least as good as in individuals without HIV.

PubMed Disclaimer

Conflict of interest statement

Aliyah SohaniConsulting or Advisory Role: AbbVie, MersanaExpert Testimony: Levin Papantonio Jason EfstathiouConsulting or Advisory Role: Blue Earth Diagnostics, AstraZeneca, Boston Scientific, Roivant, Merck, Myovant Sciences Philippe ArmandHonoraria: Merck, Bristol Myers SquibbConsulting or Advisory Role: Bristol Myers Squibb, Merck Sharp & Dohme, ADC Therapeutics, Celgene, Daiichi Sankyo, C4 Therapeutics, GenMab, Miltenyi Biotec, Enterome, Tessa Therapeutics, MorphoSys, Regeneron, Genentech/Roche, EpizymeResearch Funding: Merck Sharp & Dohme (Inst), Bristol Myers Squibb (Inst), Roche (Inst), Adaptive Biotechnologies (Inst), Affimed Therapeutics (Inst), Genentech (Inst), IGM (Inst), Kite, a Gilead Company (Inst)Travel, Accommodations, Expenses: Bristol Myers Squibb, Merck Sharp & Dohme Scott Dryden-PetersonPatents, Royalties, Other Intellectual Property: Royalties received from UpToDate, Inc for article on HIVNo other potential conflicts of interest were reported.

Figures

FIG 1
FIG 1
Estimated overall survival of Hodgkin lymphoma by HIV infection status using the Kaplan-Meier method. In this unadjusted analysis, patients with concurrent HIV infection experienced longer survival (log-rank P = .021). Shaded bands indicate 95% CI.

References

    1. Chabner BA, Efstathiou J, Dryden-Peterson S: Cancer in Botswana: The second wave of AIDS in sub-Saharan Africa. Oncologist 18:777-778, 2013 - PMC - PubMed
    1. Livingston J: Cancer in the shadow of the AIDS epidemic in Southern Africa. Oncologist 18:783-786, 2013 - PMC - PubMed
    1. Dryden-Peterson S, Medhin H, Kebabonye-Pusoentsi M, et al. : Cancer incidence following expansion of HIV treatment in Botswana. PLoS One 10:e0135602, 2015 - PMC - PubMed
    1. Avert : Global Information and Education on HIV and AIDS. https://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/...
    1. Bedimo RJ, McGinnis KA, Dunlap M, et al. : Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: Impact of immunosuppression. J Acquir Immune Defic Syndr 52:203-208, 2009 - PMC - PubMed

Publication types